Research And Development In Biotechnology (Except Nanobiotechnology) federal obligations in FY2024

541714 × FY2024 is a yearlyTrend join

Code 541714 and fiscal year 2024 share one cell. $17,821,488,389.67 is the USAspending.gov obligation amount on that cell. It is not 541711's biotechnology R&D book, not physical-engineering-and-life-sciences R&D (541715 or 541712), and not an outlay. The except-nanobiotechnology parenthetical is part of the stored NAICS title; this page does not publish a nanotech dollar split. This packet does not name contractors.

Two biotechnology R&D codes on the same FY2024 slice invite addition. Adding 541711's cell to $17,821,488,389.67 would invent a combined biotech total the packet does not publish. Correlation with trial or patent news is not causation.

FY2024 against 541714's longer obligation book

93.7% of $19,013,172,722.03 is tagged to FY2024. Other years for NAICS 541714 remain other rows. The industry hub (/industries/541714/) is the parent without a year filter. FY2024 federal spending (/fiscal-years/2024/) is the parent without a 541714 filter.

Do not add those parents into $17,821,488,389.67. Cite the figure as obligations for NAICS 541714 in FY2024, not as invoices already settled at a named campus.

2,378 541714 award records are extract-wide

2,378 is the Research And Development In Biotechnology (Except Nanobiotechnology) award-record count in this extract. It is not FY2024 awards, not unique vendors, and not a count of trials. This page does not divide $17,821,488,389.67 by 2,378 to invent a typical FY2024 R&D award.

What the 541714 FY2024 cell does not show

No outlays, no nano-versus-other split, no named primes, no state table. FEC filings do not fund these USAspending obligations. All industries (/industries/) and All spending ties (/ties/) hold other keys. Keep Research And Development In Biotechnology (Except Nanobiotechnology) and FY2024 on the citation.

Reading 541714's FY2024 overlay neighbors

Follow /industries/541714/ for NAICS 541714, /fiscal-years/2024/ for FY2024 across industries, /industries/ for the industry index, and /ties/ for other joins. Those URLs are larger than this yearlyTrend pair.

Reuse $17,821,488,389.67 only as Research And Development In Biotechnology (Except Nanobiotechnology) obligations in FY2024. The 2,378 award-record count stays on the industry extract. Filings remain on USAspending.gov. Keep Research And Development In Biotechnology (Except Nanobiotechnology) and FY2024 together when citing $17,821,488,389.67. NAICS 541714's extract-wide award-record count is 2,378, not a FY2024 census. Obligations of $17,821,488,389.67 are not outlays. Original filings remain on USAspending.gov for this 541714 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 93.7% share is $17,821,488,389.67 divided by the extract-wide $19,013,172,722.03, not a budget score. Unique recipients remain unpublished on this Research And Development In Biotechnology (Except Nanobiotechnology) FY2024 join. Agency and place-of-performance splits are omitted from this packet. Quote NAICS 541714, fiscal year 2024, and $17,821,488,389.67 in one sentence. The All industries index and All spending ties index are larger than this cell. A later USAspending ingest can restate $17,821,488,389.67 without changing the join keys. Keep Research And Development In Biotechnology (Except Nanobiotechnology) and FY2024 together when citing $17,821,488,389.67. NAICS 541714's extract-wide award-record count is 2,378, not a FY2024 census. Obligations of $17,821,488,389.67 are not outlays. Original filings remain on USAspending.gov for this 541714 × FY2024 pair. Do not add parent hubs into this yearlyTrend cell. Campaign-finance tables do not fund these USAspending obligations. The 93.7% share is $17,821,488,389.67 divided by the extract-wide $19,013,172,722.03, not a budget score. Unique recipients remain unpublished on this Research And Development In Biotechnology (Except Nanobiotechnology) FY2024 join. Agency and place-of-performance splits are omitted from this packet.

Questions

How much did except-nanobiotechnology R&D obligate in FY2024?

USAspending.gov records $17,821,488,389.67 in Research And Development In Biotechnology (Except Nanobiotechnology) obligations for FY2024 under NAICS 541714. That yearlyTrend amount is not an outlay and not the $19,013,172,722.03 extract-wide total.

Is FY2024 most of 541714's published book?

FY2024 is 93.7% of NAICS 541714's $19,013,172,722.03 extract-wide total. Other fiscal-year rows are separate cells. Do not merge 541711 into this join. 2,378 is the industry extract award-record count, not a FY2024 headcount.

Do 2,378 awards mean 2,378 FY2024 biotech grants?

No. 2,378 is 541714's extract-wide award-record count, not a FY2024 instrument list. Unique recipients and campus splits are unpublished. Obligations of $17,821,488,389.67 are not outlays. The pair is NAICS 541714 plus FY2024. The pair is NAICS 541714 plus FY2024.

Are these outlays to named research campuses?

No. $17,821,488,389.67 is an obligation aggregate. The packet names no contractors and publishes no outlay total. FEC donations do not fund this USAspending cell. USAspending.gov remains the source for NAICS 541714 in FY2024. The pair is NAICS 541714 plus FY2024.